Severe Asthma Management
Publication Date: October 1, 2019
Key Points
Key Points
Following the recent appearance of new anti-interleukin biologic agents and standardization of sputum eosinophil counts and exhaled nitric oxide fraction (FENO), ATS/ERS have added recommendations for these agents for adults with severe uncontrolled asthma and modified certain other recommendations from the 2014 guideline.
Treatment
...Tre...
Table 1...
...nti-IL-5 strategy as add-on therap...
...that a blood eosinophil cut-point ≥150...
...a blood eosinophil cut-off ≥260 µL...
...sing a FENO cut-off ≥19.5 ppb to id...
...ldren, adolescents and adults with seve...
...suggest a trial of macrolide treatment to...
...inst the use of chronic macrolide treatm...
We suggest dupilumab as add-on ther...
...able 2. Monoclonal Antibodies for Severe Asthm...